Discussion
Long-term treatment with Hemlibra (emicizumab) provided sustained protection against bleeding for up to five years in people with hemophilia A, with no new safety concerns identified, according to a large real-world study from Canada. The study, which analyzed data from 710 people with hemophilia A, found that more…